Does the media favor PCRX or SUPN?

In the previous week, Pacira BioSciences had 1 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 3 mentions for Pacira BioSciences and 2 mentions for Supernus Pharmaceuticals. Pacira BioSciences' average media sentiment score of 0.96 beat Supernus Pharmaceuticals' score of 0.94 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PCRX or NKTR?

In the previous week, Nektar Therapeutics had 1 more articles in the media than Pacira BioSciences. MarketBeat recorded 4 mentions for Nektar Therapeutics and 3 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.96 beat Nektar Therapeutics' score of 0.69 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRGO or PCRX?

In the previous week, Pacira BioSciences had 1 more articles in the media than Perrigo. MarketBeat recorded 3 mentions for Pacira BioSciences and 2 mentions for Perrigo. Pacira BioSciences' average media sentiment score of 0.96 beat Perrigo's score of 0.00 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, OMER or PCRX?

Pacira BioSciences has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros $9.89M 72.50 -$3.35M $0.70 14.16 Pacira BioSciences $726.41M 1.36 $7.03M $0.12 209.08

Is OMER or PCRX more profitable?

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Pacira BioSciences 0.70% 10.24% 5.47%

Does the media refer more to OMER or PCRX?

In the previous week, Omeros had 7 more articles in the media than Pacira BioSciences. MarketBeat recorded 10 mentions for Omeros and 3 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.96 beat Omeros' score of -0.20 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ASMB or PCRX?

In the previous week, Pacira BioSciences had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 3 mentions for Pacira BioSciences and 2 mentions for Assembly Biosciences. Pacira BioSciences' average media sentiment score of 0.96 beat Assembly Biosciences' score of 0.93 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pacira BioSciences (PCRX) Competitors

$25.09 -0.15 (-0.59%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$25.41 +0.32 (+1.27%)

As of 06/29/2026 07:56 PM Eastern

Compare

PCRX vs. SUPN, NKTR, PRGO, OMER, and ASMB

Should you buy Pacira BioSciences stock or one of its competitors? MarketBeat compares Pacira BioSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pacira BioSciences include Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Perrigo (PRGO), Omeros (OMER), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceuticals" industry.

How does Pacira BioSciences compare to Supernus Pharmaceuticals?

Pacira BioSciences (NASDAQ:PCRX) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Pacira BioSciences presently has a consensus target price of $29.40, indicating a potential upside of 17.18%. Supernus Pharmaceuticals has a consensus target price of $62.17, indicating a potential upside of 32.83%. Given Supernus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Pacira BioSciences has a net margin of 0.70% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

In the previous week, Pacira BioSciences had 1 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 3 mentions for Pacira BioSciences and 2 mentions for Supernus Pharmaceuticals. Pacira BioSciences' average media sentiment score of 0.96 beat Supernus Pharmaceuticals' score of 0.94 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.36	$7.03M	$0.12	209.08
Supernus Pharmaceuticals	$718.95M	3.78	-$38.55M	-$0.51	N/A

99.7% of Pacira BioSciences shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pacira BioSciences has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Summary

Pacira BioSciences and Supernus Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Nektar Therapeutics?

Pacira BioSciences (NASDAQ:PCRX) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Pacira BioSciences currently has a consensus price target of $29.40, indicating a potential upside of 17.18%. Nektar Therapeutics has a consensus price target of $149.63, indicating a potential upside of 128.82%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pacira BioSciences has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Pacira BioSciences has a net margin of 0.70% compared to Nektar Therapeutics' net margin of -284.18%. Pacira BioSciences' return on equity of 10.24% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

In the previous week, Nektar Therapeutics had 1 more articles in the media than Pacira BioSciences. MarketBeat recorded 4 mentions for Nektar Therapeutics and 3 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.96 beat Nektar Therapeutics' score of 0.69 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.36	$7.03M	$0.12	209.08
Nektar Therapeutics	$55.23M	40.01	-$164.08M	-$8.42	N/A

Summary

Pacira BioSciences beats Nektar Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Perrigo?

Perrigo (NYSE:PRGO) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Pacira BioSciences has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.33	-$1.43B	-$13.10	N/A
Pacira BioSciences	$726.41M	1.36	$7.03M	$0.12	209.08

95.9% of Perrigo shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 0.4% of Perrigo shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Perrigo has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

In the previous week, Pacira BioSciences had 1 more articles in the media than Perrigo. MarketBeat recorded 3 mentions for Pacira BioSciences and 2 mentions for Perrigo. Pacira BioSciences' average media sentiment score of 0.96 beat Perrigo's score of 0.00 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Perrigo presently has a consensus target price of $19.33, indicating a potential upside of 92.76%. Pacira BioSciences has a consensus target price of $29.40, indicating a potential upside of 17.18%. Given Perrigo's higher probable upside, research analysts plainly believe Perrigo is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Pacira BioSciences has a net margin of 0.70% compared to Perrigo's net margin of -43.50%. Pacira BioSciences' return on equity of 10.24% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Pacira BioSciences	0.70%	10.24%	5.47%

Summary

Pacira BioSciences beats Perrigo on 13 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Omeros?

Omeros (NASDAQ:OMER) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Omeros presently has a consensus price target of $38.00, indicating a potential upside of 283.45%. Pacira BioSciences has a consensus price target of $29.40, indicating a potential upside of 17.18%. Given Omeros' stronger consensus rating and higher probable upside, research analysts clearly believe Omeros is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Omeros has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

In the previous week, Omeros had 7 more articles in the media than Pacira BioSciences. MarketBeat recorded 10 mentions for Omeros and 3 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.96 beat Omeros' score of -0.20 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Pacira BioSciences	0.70%	10.24%	5.47%

Pacira BioSciences has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	$9.89M	72.50	-$3.35M	$0.70	14.16
Pacira BioSciences	$726.41M	1.36	$7.03M	$0.12	209.08

48.8% of Omeros shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 10.5% of Omeros shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Omeros beats Pacira BioSciences on 9 of the 17 factors compared between the two stocks.

How does Pacira BioSciences compare to Assembly Biosciences?

Assembly Biosciences (NASDAQ:ASMB) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Pacira BioSciences has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	5.93	-$6.12M	-$0.11	N/A
Pacira BioSciences	$726.41M	1.36	$7.03M	$0.12	209.08

Assembly Biosciences has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

In the previous week, Pacira BioSciences had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 3 mentions for Pacira BioSciences and 2 mentions for Assembly Biosciences. Pacira BioSciences' average media sentiment score of 0.96 beat Assembly Biosciences' score of 0.93 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has a net margin of 0.70% compared to Assembly Biosciences' net margin of -8.98%. Pacira BioSciences' return on equity of 10.24% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Pacira BioSciences	0.70%	10.24%	5.47%

Assembly Biosciences presently has a consensus target price of $44.00, indicating a potential upside of 63.20%. Pacira BioSciences has a consensus target price of $29.40, indicating a potential upside of 17.18%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Assembly Biosciences is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 5.1% of Assembly Biosciences shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Pacira BioSciences beats Assembly Biosciences on 11 of the 16 factors compared between the two stocks.

Get Pacira BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCRX vs. The Competition

Export

Metric	Pacira BioSciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$993.14M	$3.62B	$6.85B	$12.20B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	209.10	20.93	26.02	24.36
Price / Sales	1.36	345.52	549.85	102.46
Price / Cash	6.54	62.10	29.09	36.93
Price / Book	1.56	8.71	10.98	6.49
Net Income	$7.03M	$23.87M	$3.57B	$336.61M
7 Day Performance	6.72%	3.59%	2.60%	1.25%
1 Month Performance	8.05%	1.73%	0.93%	0.24%
1 Year Performance	4.98%	69.03%	36.40%	30.16%

Pacira BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
PCRX Pacira BioSciences	2.9849 of 5 stars	$25.09 -0.6%	$29.40 +17.2%	+6.9%	$993.14M	$726.41M	209.10	720
SUPN Supernus Pharmaceuticals	2.6863 of 5 stars	$44.48 +0.2%	$62.17 +39.8%	+50.2%	$2.58B	$718.95M	N/A	580
NKTR Nektar Therapeutics	2.8853 of 5 stars	$65.70 +7.7%	$149.63 +127.7%	+153.8%	$2.06B	$55.23M	N/A	220
PRGO Perrigo	3.5462 of 5 stars	$9.60 -6.3%	$19.33 +101.3%	-62.2%	$1.42B	$4.25B	N/A	8,100
OMER Omeros	3.4531 of 5 stars	$10.33 +0.5%	$40.33 +290.4%	+209.7%	$744.02M	N/A	14.76	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCRX) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacira BioSciences (PCRX) Competitors

PCRX vs. SUPN, NKTR, PRGO, OMER, and ASMB

How does Pacira BioSciences compare to Supernus Pharmaceuticals?

Summary

How does Pacira BioSciences compare to Nektar Therapeutics?

Summary

How does Pacira BioSciences compare to Perrigo?

Summary

How does Pacira BioSciences compare to Omeros?

Summary

How does Pacira BioSciences compare to Assembly Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX vs. The Competition

Pacira BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacira BioSciences (PCRX) Competitors

PCRX vs. SUPN, NKTR, PRGO, OMER, and ASMB

How does Pacira BioSciences compare to Supernus Pharmaceuticals?

Do analysts prefer PCRX or SUPN?

Is PCRX or SUPN more profitable?

Does the media favor PCRX or SUPN?

Which has higher valuation and earnings, PCRX or SUPN?

Do institutionals and insiders believe in PCRX or SUPN?

Which has more risk and volatility, PCRX or SUPN?

Summary

How does Pacira BioSciences compare to Nektar Therapeutics?

Do analysts recommend PCRX or NKTR?

Do insiders and institutionals believe in PCRX or NKTR?

Which has more volatility & risk, PCRX or NKTR?

Is PCRX or NKTR more profitable?

Does the media favor PCRX or NKTR?

Which has higher earnings and valuation, PCRX or NKTR?

Summary

How does Pacira BioSciences compare to Perrigo?

Which has stronger valuation & earnings, PRGO or PCRX?

Do insiders & institutionals have more ownership in PRGO or PCRX?

Which has more volatility & risk, PRGO or PCRX?

Does the media refer more to PRGO or PCRX?

Do analysts prefer PRGO or PCRX?

Is PRGO or PCRX more profitable?

Summary

How does Pacira BioSciences compare to Omeros?

Do analysts rate OMER or PCRX?

Which has more risk and volatility, OMER or PCRX?

Does the media refer more to OMER or PCRX?

Is OMER or PCRX more profitable?

Which has better valuation and earnings, OMER or PCRX?

Do institutionals and insiders have more ownership in OMER or PCRX?

Summary

How does Pacira BioSciences compare to Assembly Biosciences?

Which has better valuation & earnings, ASMB or PCRX?

Which has more risk and volatility, ASMB or PCRX?

Does the media favor ASMB or PCRX?

Is ASMB or PCRX more profitable?

Do analysts recommend ASMB or PCRX?

Do institutionals & insiders believe in ASMB or PCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX vs. The Competition

Pacira BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools